LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities falls 40.6% from a year ago
Other non-current liabilities stood at $1.14M at the end of Q1 FY2026, down 40.6% from a year earlier and down 14.9% from the prior quarter. Over 3 fiscal years it compounded at -62.6% a year.
Context
- Other non-current liabilities amounted to 0.3% of total assets at the end of Q1 FY2026, down 9.7 pp from a year earlier.
- Other non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -40.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.34M USD
- Year-over-year change
- -98.8%
- 3-year CAGR
- -62.6%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34M | -98.8% |
| FY2024 | 2024-12-31 | 116.76M | +50.6% |
| FY2023 | 2023-12-31 | 77.52M | +201.8% |
| FY2022 | 2022-12-31 | 25.69M | — |
Other Non-current Liabilities vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 other non-current liabilities of $1.14M is the 7th highest of the 10 companies compared; the peer median is $16.22M.
- Its year-over-year change of -40.6% is the lowest of 5, against a peer median of +1061.3%.
- Other non-current liabilities amounts to 0.3% of total assets for LBRX, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $292.69B | +487717.0% | +32.5% | 307.8% | |
| Jun 2026 | $205.19M | +1864.7% | +144.4% | 17.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $52.96M | — | -59.9% | 34.4% |
| Sep 2026 | $17.12M | +23.3% | +28.2% | 1.0% | |
| Mar 2026 | $16.22M | — | +114.0% | 5.9% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $1.86M | +258.0% | +226.1% | 0.2% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $1.14M | -40.6% | -62.6% | 0.3% |
| Mar 2026 | $0 | — | — | 0.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $16.22M | +1061.3% | +73.3% | 1.0% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.